Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Canadian researchers analyzed the reasons why people declined a nurse’s offer of PrEP.
Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.
Here are the HIV treatment news stories with the most views this year.
Plus: Tell your representatives to support the PrEP Access and Coverage Act. Here’s how.
The funding arrives via Gilead Sciences’ COMPASS Initiative.
The U.S. Health Department launched Ready, Set, PrEP to provide the HIV prevention med at no cost.
An analysis of veterans seeking PrEP found that they often had to be extraordinarily persistent in their efforts to receive a prescription.
Funding arrives via Gilead Sciences and its TRANScend Community Impact Fund.
Studies indicate that there is a very low likelihood that people with HIV have preexisting resistance to the medication.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
The complaint alleges the company has profited from research spearheaded by the CDC.
The pop star’s party is named after the HIV prevention drug and is meant as an homage to ’80s-era queer nightlife.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
Relying on Gilead’s payment assistance program to pay for Truvada delayed their first dose by an additional 16 days.
The investigational, injectable, long-acting antiretroviral is a potential new option for those with multidrug resistance.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.